Stocksigma LogoStocksigma Logo

Windlas Biotech Delivers Strong Q2 and H1 FY27 Results Driven by Core CDMO Expansion

Windlas Biotech reported Q2FY27 revenue of Rs. 264 crore, up 19% YoY, marked by its 15th consecutive quarter of record sales

Windlas Biotech Delivers Strong Q2 and H1 FY27 Results Driven by Core CDMO Expansion

Windlas Biotech Ltd 路 Press Release 路 05 Nov 2026, 11:18 pm

Windlas Biotech Delivers Strong Q2 and H1 FY27 Results Driven by Core CDMO Expansion Windlas Biotech reported Q2FY27 revenue of Rs. 264 crore, up 19% YoY, marked by its 15th consecutive quarter of record sales. Adjusted EBITDA rose 20% YoY to Rs. 36 crore with a 13.7% margin, while adjusted PAT increased 29% YoY to Rs. 25 crore. For H1FY27, revenue reached Rs. 512 crore (up 18% YoY), driven by Generic Formulations CDMO sales rising 32% YoY to Rs. 422 crore. The company commercialized Plant-6 in Sep'26, received EU GMP certification for Plant-4 and Plant-5, and maintained net liquidity of Rs. 223 crore.

Original exchange filing (PDF)

More announcements from Windlas Biotech Ltd

All Windlas Biotech Ltd announcements